Furthermore, the NKCE IPH6401/SAR’514 targeting BCMA, CD16, and NKp46 is in a phase 1/2 trial for patients with relapsed/refractory multiple myeloma or light-chain amyloidosis (NCT05839626). Here, TNFRSF17 is linked to plasma cell myeloma.